Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com//news-release/2024/03/12/2844418/0/en/Immunovant-Awarded-U-S-Patent-for-IMVT-1402.html
https://www.globenewswire.com//news-release/2024/02/12/2827408/0/en/Immunovant-Reports-Financial-Results-and-Provides-Corporate-Updates-for-the-Quarter-Ended-December-31-2023.html
https://www.globenewswire.com//news-release/2024/01/03/2803253/0/en/Immunovant-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html
https://www.fiercebiotech.com/biotech/immunovant-stakes-claim-fcrn-niche-posting-midphase-graves-data-and-plotting-next-steps
https://endpts.com/immunovant-unveils-positive-early-data-for-phii-graves-disease-drug/
https://www.globenewswire.com//news-release/2023/12/20/2799661/0/en/Immunovant-Reports-Positive-Initial-Phase-2-Results-for-Batoclimab-in-Graves-Disease.html
https://www.globenewswire.com//news-release/2023/11/28/2786806/0/en/Immunovant-Announces-Positive-IMVT-1402-Initial-600-mg-MAD-Results-that-Confirm-Best-in-Class-Potential.html
https://www.globenewswire.com//news-release/2023/11/13/2778984/0/en/Immunovant-to-Present-at-Upcoming-Investor-Conferences.html
https://www.globenewswire.com//news-release/2023/11/09/2777177/0/en/Immunovant-Reports-Financial-Results-and-Provides-Corporate-Updates-for-the-Quarter-Ended-September-30-2023.html
https://www.globenewswire.com//news-release/2023/10/02/2753182/0/en/Immunovant-Announces-Closing-of-Upsized-Common-Stock-Financing-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html